Stephen A Ward

List of Publications by Year
in descending order

308 papers	15,251 citations	14655 66 h-index	32842 100 g-index
332 all docs	332 docs citations	332 times ranked	11544 citing authors

#	Article	IF	Citations
1	Artemisinins target the SERCA of Plasmodium falciparum. Nature, 2003, 424, 957-961.	27.8	904
2	The Molecular Mechanism of Action of Artemisininâ€"The Debate Continues. Molecules, 2010, 15, 1705-1721.	3.8	474
3	4-Aminoquinolinesâ€"Past, present, and future; A chemical perspective. , 1998, 77, 29-58.		242
4	Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites <i>Plasmodium falciparum</i> 3D7. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2080-2085.	7.1	209
5	Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends in Parasitology, 2003, 19, 232-239.	3.3	208
6	Access to Hematin: The Basis of Chloroquine Resistance. Molecular Pharmacology, 1998, 54, 170-179.	2.3	203
7	Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clinical Pharmacology and Therapeutics, 1989, 45, 72-79.	4.7	184
8	A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO Journal, 2005, 24, 2294-2305.	7.8	168
9	Relationship between Antimalarial Drug Activity, Accumulation, and Inhibition of Heme Polymerization in <i>Plasmodium falciparum</i> In Vitro. Antimicrobial Agents and Chemotherapy, 1998, 42, 682-686.	3.2	166
10	Evidence for a Central Role for PfCRT in Conferring Plasmodium falciparum Resistance to Diverse Antimalarial Agents. Molecular Cell, 2004, 15, 867-877.	9.7	157
11	Cellular Uptake of Chloroquine Is Dependent on Binding to Ferriprotoporphyrin IX and Is Independent of NHE Activity in Plasmodium falciparum. Journal of Cell Biology, 1999, 145, 363-376.	5.2	155
12	Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance. Molecular Microbiology, 2005, 56, 323-333.	2.5	154
13	Antimalarial pharmacology and therapeutics of atovaquone. Journal of Antimicrobial Chemotherapy, 2013, 68, 977-985.	3.0	147
14	Generation of quinolone antimalarials targeting the <i>Plasmodium falciparum</i> mitochondrial respiratory chain for the treatment and prophylaxis of malaria. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8298-8303.	7.1	143
15	Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infectious Diseases, The, 2007, 7, 136-144.	9.1	136
16	Chloroquine resistance before and after its withdrawal in Kenya. Malaria Journal, 2009, 8, 106.	2.3	136
17	P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?. Aids, 2001, 15, 1353-1358.	2.2	131
18	Isoquine and Related Amodiaquine Analogues:Â A New Generation of Improved 4-Aminoquinoline Antimalarials. Journal of Medicinal Chemistry, 2003, 46, 4933-4945.	6.4	130

#	Article	IF	Citations
19	Anti-<i>Wolbachia</i> drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis. Parasitology, 2014, 141, 119-127.	1.5	130
20	Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2004, 71, 380-394.	1.4	126
21	Novel Short Chain Chloroquine Analogues Retain Activity Against Chloroquine Resistant K1Plasmodium falciparum. Journal of Medicinal Chemistry, 2002, 45, 4975-4983.	6.4	121
22	Functional Characterization and Target Validation of Alternative Complex I of Plasmodium falciparum Mitochondria. Antimicrobial Agents and Chemotherapy, 2006, 50, 1841-1851.	3.2	120
23	Low Levels of Pyrazinamide and Ethambutol in Children with Tuberculosis and Impact of Age, Nutritional Status, and Human Immunodeficiency Virus Infection. Antimicrobial Agents and Chemotherapy, 2006, 50, 407-413.	3.2	120
24	Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. Tuberculosis, 2007, 87, 248-255.	1.9	119
25	Prioritization of Antiâ€SARSâ€Covâ€2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. Clinical Pharmacology and Therapeutics, 2020, 108, 775-790.	4.7	118
26	Mechanism-Based Design of Parasite-Targeted Artemisinin Derivatives:â€‰ Synthesis and Antimalarial Activity of New Diamine Containing Analogues. Journal of Medicinal Chemistry, 2002, 45, 1052-1063.	6.4	116
27	Evidence for a Common Nonâ€Heme Chelatableâ€Ironâ€Dependent Activation Mechanism for Semisynthetic and Synthetic Endoperoxide Antimalarial Drugs. Angewandte Chemie - International Edition, 2007, 46, 6278-6283.	13.8	116
28	Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential. Journal of Antimicrobial Chemotherapy, 2014, 69, 1005-1016.	3.0	116
29	Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes. British Journal of Clinical Pharmacology, 2000, 49, 313-322.	2.4	113
30	Identification of a 1,2,4,5â€Tetraoxane Antimalarial Drugâ€Development Candidate (RKAâ€‰182) with Superior Properties to the Semisynthetic Artemisinins. Angewandte Chemie - International Edition, 2010, 49, 5693-5697.	13.8	111
31	Acidification of the Malaria Parasite's Digestive Vacuole by a H+-ATPase and a H+-pyrophosphatase. Journal of Biological Chemistry, 2003, 278, 5605-5612.	3.4	107
32	Synthesis, Antimalarial Activity, and Molecular Modeling of Tebuquine Analogues. Journal of Medicinal Chemistry, 1997, 40, 437-448.	6.4	105
33	A Medicinal Chemistry Perspective on 4-Aminoquinoline Antimalarial Drugs. Current Topics in Medicinal Chemistry, 2006, 6, 479-507.	2.1	104
34	Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data. BMC Medicine, 2016, 14, 79.	5.5	104
35	Diamidine Compounds: Selective Uptake and Targeting in<i>Plasmodium falciparum</i>. Molecular Pharmacology, 2001, 59, 1298-1306.	2.3	101
36	Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2018, 18, 615-626.	9.1	99

#	Article	IF	Citations
37	Antimalarial and Antitumor Evaluation of Novel C-10 Non-Acetal Dimers of 10Î²-(2-Hydroxyethyl)deoxoartemisinin. Journal of Medicinal Chemistry, 2004, 47, 1290-1298.	6.4	97
38	Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Lancet, The, 2004, 363, 1843-1848.	13.7	97
39	Inhibiting Plasmodium cytochrome bc1: a complex issue. Current Opinion in Chemical Biology, 2010, 14, 440-446.	6.1	97
40	Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. European Journal of Clinical Pharmacology, 2006, 62, 367-371.	1.9	95
41	Identification, Design and Biological Evaluation of Bisaryl Quinolones Targeting <i>Plasmodium falciparum</i> Type II NADH:Quinone Oxidoreductase (PfNDH2). Journal of Medicinal Chemistry, 2012, 55, 1831-1843.	6.4	94
42	Antimalarial activity of primaquine operates via a two-step biochemical relay. Nature Communications, 2019, 10, 3226.	12.8	94
43	Comparative folate metabolism in humans and malaria parasites (part I): pointers for malaria treatment from cancer chemotherapy. Trends in Parasitology, 2005, 21, 292-298.	3.3	93
44	Industrial scale high-throughput screening delivers multiple fast acting macrofilaricides. Nature Communications, 2019, 10, 11.	12.8	93
45	Synthesis, Antimalarial Activity, Biomimetic Iron(II) Chemistry, and in Vivo Metabolism of Novel, Potent C-10-Phenoxy Derivatives of Dihydroartemisinin. Journal of Medicinal Chemistry, 2001, 44, 58-68.	6.4	92
46	Antimalarial 4(1H)-pyridones bind to the Q _i site of cytochrome <i>bc</i> ₁. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 755-760.	7.1	90
47	The role of drug accumulation in 4-aminoquinoline antimalarial potency. Biochemical Pharmacology, 1996, 52, 723-733.	4.4	88
48	PfCRT and the trans-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX. Molecular Microbiology, 2006, 62, 238-251.	2.5	85
49	Acridinediones: Selective and Potent Inhibitors of the Malaria Parasite Mitochondrial bc1 Complex. Molecular Pharmacology, 2008, 73, 1347-1355.	2.3	85
50	Clinical status and implications of antimalarial drug resistance. Microbes and Infection, 2002, 4, 157-164.	1.9	84
51	Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. Aids, 2005, 19, 2097-2102.	2.2	84
52	Design and synthesis of orally active dispiro 1,2,4,5-tetraoxanes; synthetic antimalarials with superior activity to artemisinin. Organic and Biomolecular Chemistry, 2006, 4, 4431.	2.8	83
53	Rapid chloroquine efflux phenotype in both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. Biochemical Pharmacology, 1992, 44, 1317-1324.	4.4	81
54	Central Role of Hemoglobin Degradation in Mechanisms of Action of 4-Aminoquinolines, Quinoline Methanols, and Phenanthrene Methanols. Antimicrobial Agents and Chemotherapy, 1998, 42, 2973-2977.	3.2	81

#	ARTICLE	IF	CITATIONS
55	Characterization of the choline carrier of Plasmodium falciparum: a route for the selective delivery of novel antimalarial drugs. Blood, 2004, 104, 3372-3377.	1.4	80
56	Recent highlights in antimalarial drug resistance and chemotherapy research. Trends in Parasitology, 2008, 24, 537-544.	3.3	80
57	Candidate Selection and Preclinical Evaluation of <i>N</i>-<i>tert</i>-Butyl Isoquine (GSK369796), An Affordable and Effective 4-Aminoquinoline Antimalarial for the 21st Century. Journal of Medicinal Chemistry, 2009, 52, 1408-1415.	6.4	80
58	Antimalarial chemotherapy: young guns or back to the future?. Trends in Parasitology, 2003, 19, 479-487.	3.3	79
59	The Effect of Fluorine Substitution on the Metabolism and Antimalarial Activity of Amodiaquine. Journal of Medicinal Chemistry, 1994, 37, 1362-1370.	6.4	78
60	Amodiaquine accumulation in Plasmodium falciparum as a possible explanation for its superior antimalarial activity over chloroquine. Molecular and Biochemical Parasitology, 1996, 80, 15-25.	1.1	78
61	Two-Step Synthesis of Achiral Dispiro-1,2,4,5-tetraoxanes with Outstanding Antimalarial Activity, Low Toxicity, and High-Stability Profiles. Journal of Medicinal Chemistry, 2008, 51, 2170-2177.	6.4	78
62	Cytochrome b Mutation Y268S Conferring Atovaquone Resistance Phenotype in Malaria Parasite Results in Reduced Parasite bc1 Catalytic Turnover and Protein Expression. Journal of Biological Chemistry, 2012, 287, 9731-9741.	3.4	77
63	A Click Chemistryâ€Based Proteomic Approach Reveals that 1,2,4â€Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile. Angewandte Chemie - International Edition, 2016, 55, 6401-6405.	13.8	76
64	The toxicity of artemisinin and related compounds on neuronal and glial cells in culture. Chemico-Biological Interactions, 1995, 96, 263-271.	4.0	75
65	The effect of dose on the antimalarial efficacy of artemetherâ€“lumefantrine: a systematic review and pooled analysis of individual patient data. Lancet Infectious Diseases, The, 2015, 15, 692-702.	9.1	74
66	The Digestive Food Vacuole of the Malaria Parasite Is a Dynamic Intracellular Ca2+ Store. Journal of Biological Chemistry, 2003, 278, 27910-27915.	3.4	73
67	A comparison of the phenomenology and genetics of multidrug resistance in cancer cells and quinoline resistance in Plasmodium falciparum. , 1998, 77, 1-28.		71
68	Co(thd)2: a superior catalyst for aerobic epoxidation and hydroperoxysilylation of unactivated alkenes: application to the synthesis of spiro-1,2,4-trioxanes. Tetrahedron Letters, 2003, 44, 8135-8138.	1.4	69
69	The malaria parasite type II NADH:quinone oxidoreductase: an alternative enzyme for an alternative lifestyle. Trends in Parasitology, 2007, 23, 305-310.	3.3	69
70	Heme Binding Contributes to Antimalarial Activity of Bis-Quaternary Ammoniums. Antimicrobial Agents and Chemotherapy, 2003, 47, 2584-2589.	3.2	67
71	Preclinical development of an oral anti- <i>Wolbachia</i> macrolide drug for the treatment of lymphatic filariasis and onchocerciasis. Science Translational Medicine, 2019, 11, .	12.4	67
72	Co-transmission of Related Malaria Parasite Lineages Shapes Within-Host Parasite Diversity. Cell Host and Microbe, 2020, 27, 93-103.e4.	11.0	67

#	Article	IF	Citations
73	Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis. Scientific Reports, 2017, 7, 210.	3.3	65
74	Semi-synthetic and synthetic 1,2,4-trioxaquines and 1,2,4-trioxolaquines: synthesis, preliminary SAR and comparison with acridine endoperoxide conjugates. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2038-2043.	2.2	64
75	Diagnostics for schistosomiasis in Africa and Arabia: a review of present options in control and future needs for elimination. Parasitology, 2014, 141, 1947-1961.	1.5	63
76	A carbonyl oxide route to antimalarial yingzhaosu A analogues: Synthesis and antimalarial activity. Tetrahedron Letters, 1998, 39, 6065-6068.	1.4	61
77	Coartem (Artemetherâ€Łumefantrine) in Africa: The Beginning of the End?. Journal of Infectious Diseases, 2005, 192, 1303-1304.	4.0	61
78	Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data. BMC Medicine, 2015, 13, 212.	5.5	61
79	Design and synthesis of novel 2-pyridone peptidomimetic falcipain 2/3 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4210-4214.	2.2	60
80	Biomimetic Fe(II)-Mediated Degradation of Arteflene (Ro-42-1611). The First EPR Spin-Trapping Evidence for the Previously Postulated Secondary Carbon-Centered Cyclohexyl Radical. Journal of Organic Chemistry, 2000, 65, 1578-1582.	3.2	59
81	Plasmodium falciparum: sacrificing membrane to grow crystals?. Trends in Parasitology, 2003, 19, 23-26.	3.3	59
82	Comparative folate metabolism in humans and malaria parasites (part II): activities as yet untargeted or specific to Plasmodium. Trends in Parasitology, 2005, 21, 334-339.	3.3	59
83	Population Pharmacokinetics of Artesunate and Dihydroartemisinin following Intra-Rectal Dosing of Artesunate in Malaria Patients. PLoS Medicine, 2006, 3, e444.	8.4	59
84	Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. Malaria Journal, 2009, 8, 204.	2.3	59
85	Novel, Potent, Semisynthetic Antimalarial Carba Analogues of the First-Generation 1,2,4-Trioxane Artemether. Journal of Medicinal Chemistry, 1999, 42, 5487-5493.	6.4	58
86	New 4-Aminoquinoline Mannich Base Antimalarials. 1. Effect of an Alkyl Substituent in the 5â€˜-Position of the 4â€˜-Hydroxyanilino Side Chain. Journal of Medicinal Chemistry, 1999, 42, 2747-2751.	6.4	58
87	Therapy of Falciparum Malaria in Sub-Saharan Africa: from Molecule to Policy. Clinical Microbiology Reviews, 2004, 17, 612-637.	13.6	58
88	Application of Thiolâˆ'Olefin Co-oxygenation Methodology to a New Synthesis of the 1,2,4-Trioxane Pharmacophore. Organic Letters, 2004, 6, 3035-3038.	4.6	58
89	Chlorproguanilâˆ'Dapsoneâˆ'Artesunate versus Artemetherâˆ'Lumefantrine: A Randomized, Double-Blind Phase III Trial in African Children and Adolescents with Uncomplicated Plasmodium falciparum Malaria. PLoS ONE, 2009, 4, e6682.	2.5	58
90	A Requiem for Chloroquine. Science, 2002, 298, 74-75.	12.6	57

#	ARTICLE	IF	CITATIONS
91	Chemosensitization of Plasmodium falciparum by Probenecid In Vitro. Antimicrobial Agents and Chemotherapy, 2003, 47, 2108-2112.	3.2	57
92	AWZ1066S, a highly specific anti- <i>Wolbachia</i> drug candidate for a short-course treatment of filariasis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1414-1419.	7.1	57
93	Design and Synthesis of Endoperoxide Antimalarial Prodrug Models. Angewandte Chemie - International Edition, 2004, 43, 4193-4197.	13.8	56
94	Synthesis, Antimalarial Activity, and Preclinical Pharmacology of a Novel Series of 4â€²-Fluoro and 4â€²-Chloro Analogues of Amodiaquine. Identification of a Suitable â€œBack-Upâ€•Compound for <i>N-tert</i>-Butyl Isoquine. Journal of Medicinal Chemistry, 2009, 52, 1828-1844.	6.4	56
95	Targeting the mitochondrial electron transport chain of <i>Plasmodium falciparum:</i> new strategies towards the development of improved antimalarials for the elimination era. Future Medicinal Chemistry, 2013, 5, 1573-1591.	2.3	55
96	Regioselective Mukaiyama hydroperoxysilylation of 2-alkyl- or 2-aryl-prop-2-en-1-ols: application to a new synthesis of 1,2,4-trioxanes. Tetrahedron Letters, 2001, 42, 4569-4571.	1.4	54
97	HDQ, a Potent Inhibitor of Plasmodium falciparum Proliferation, Binds to the Quinone Reduction Site of the Cytochrome bc 1 Complex. Antimicrobial Agents and Chemotherapy, 2012, 56, 3739-3747.	3.2	53
98	The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. Contraception, 1991, 43, 305-316.	1.5	52
99	Modular Synthesis and in Vitro and in Vivo Antimalarial Assessment of C-10 Pyrrole Mannich Base Derivatives of Artemisinin. Journal of Medicinal Chemistry, 2010, 53, 633-640.	6.4	52
100	Design, synthesis and antimalarial/anticancer evaluation of spermidine linked artemisinin conjugates designed to exploit polyamine transporters in Plasmodium falciparum and HL-60 cancer cell lines. Bioorganic and Medicinal Chemistry, 2010, 18, 2586-2597.	3.0	51
101	Identification, Design and Biological Evaluation of Heterocyclic Quinolones Targeting <i>Plasmodium falciparum</i> Type II NADH:Quinone Oxidoreductase (PfNDH2). Journal of Medicinal Chemistry, 2012, 55, 1844-1857.	6.4	51
102	The proliferating cell hypothesis: a metabolic framework for Plasmodium growth and development. Trends in Parasitology, 2014, 30, 170-175.	3.3	51
103	A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance. Nature Communications, 2017, 8, 15159.	12.8	51
104	Selective determination, in plasma, of artemether and its major metabolite, dihydroartemisinin, by high-performance liquid chromatography with ultraviolet detection. Biomedical Applications, 1992, 583, 131-136.	1.7	50
105	Antitumour and antimalarial activity of artemisininâ€“acridine hybrids. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2033-2037.	2.2	50
106	Glutathione Transport: A New Role for PfCRT in Chloroquine Resistance. Antioxidants and Redox Signaling, 2013, 19, 683-695.	5.4	50
107	Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes. Journal of Steroid Biochemistry and Molecular Biology, 1991, 38, 219-225.	2.5	49
108	Vacuolar acidification and chloroquine sensitivity in plasmodium falciparum. Biochemical Pharmacology, 1992, 43, 1219-1227.	4.4	49

#	Article	IF	Citations
109	Enhanced in vitro neurotoxicity of artemisinin derivatives in the presence of haemin. Biochemical Pharmacology, 1997, 53, 5-10.	4.4	49
110	Enantiomeric 1,2,4-Trioxanes Display Equivalent in vitro Antimalarial Activity Versus Plasmodium falciparum Malaria Parasites: Implications for the Molecular Mechanism of Action of the Artemisinins. ChemBioChem, 2005, 6, 2048-2054.	2.6	49
111	Relationship of global chloroquine transport and reversal of resistance in Plasmodium falciparum. Molecular and Biochemical Parasitology, 1994, 63, 87-94.	1.1	48
112	Antitubercular pharmacodynamics of phenothiazines. Journal of Antimicrobial Chemotherapy, 2013, 68, 869-880.	3.0	48
113	In vitro selection of halofantrine resistance in Plasmodium falciparum is not associated with increased expression of Pgh1. Molecular and Biochemical Parasitology, 1996, 83, 35-46.	1.1	47
114	Glycerol: An unexpected major metabolite of energy metabolism by the human malaria parasite. Malaria Journal, 2009, 8, 38.	2.3	47
115	Comparison of the Reactivity of Antimalarial 1,2,4,5-Tetraoxanes with 1,2,4-Trioxolanes in the Presence of Ferrous Iron Salts, Heme, and Ferrous Iron Salts/Phosphatidylcholine. Journal of Medicinal Chemistry, 2011, 54, 6443-6455.	6.4	47
116	Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis. Malaria Journal, 2015, 14, 359.	2.3	47
117	Albendazole and antibiotics synergize to deliver short-course anti- <i>Wolbachia</i> curative treatments in preclinical models of filariasis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9712-E9721.	7.1	47
118	Current drug development portfolio for antimalarial therapies. Current Opinion in Pharmacology, 2005, 5, 473-478.	3.5	46
119	Discovery of Potent Small-Molecule Inhibitors of Multidrug-Resistant <i>Plasmodium falciparum</i> Using a Novel Miniaturized High-Throughput Luciferase-Based Assay. Antimicrobial Agents and Chemotherapy, 2010, 54, 3597-3604.	3.2	46
120	The Molecular Basis of Folate Salvage in Plasmodium falciparum. Journal of Biological Chemistry, 2011, 286, 44659-44668.	3.4	46
121	Dose prediction for repurposing nitazoxanide in SARSâ€CoVâ€2 treatment or chemoprophylaxis. British Journal of Clinical Pharmacology, 2021, 87, 2078-2088.	2.4	46
122	The biomimetic iron-mediated degradation of arteflene (Ro-42-1611),an endoperoxide antimalarial: Implications for the mechanism of antimalarial activity. Tetrahedron Letters, 1997, 38, 4263-4266.	1.4	45
123	Association Between the pfmdr1 Gene and In Vitro Artemether and Lumefantrine Sensitivity in Thai Isolates of Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene, 2010, 83, 1005-1009.	1.4	45
124	Functional Correlation of P-Glycoprotein Expression and Genotype with Expression of the Human Immunodeficiency Virus Type 1 Coreceptor CXCR4. Journal of Virology, 2004, 78, 12022-12029.	3.4	44
125	Pharmacokinetics of Rifampin in Peruvian Tuberculosis Patients with and without Comorbid Diabetes or HIV. Antimicrobial Agents and Chemotherapy, 2012, 56, 2357-2363.	3.2	43
126	Development and Validation of a High-Throughput Anti-Wolbachia Whole-Cell Screen: A Route to Macrofilaricidal Drugs against Onchocerciasis and Lymphatic Filariasis. Journal of Biomolecular Screening, 2015, 20, 64-69.	2.6	43

#	Article	IF	Citations
127	The safety and kinetics of intramuscular quinine in Malawian children with moderately severe falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1990, 84, 482-487.	1.8	42
128	Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet?. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 341-346.	1.8	40
129	Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. British Journal of Pharmacology, 2008, 155, 875-883.	5.4	40
130	Quantification of rifampicin in human plasma and cerebrospinal fluid by a highly sensitive and rapid liquid chromatographicâ€"tandem mass spectrometric method. Journal of Pharmaceutical and Biomedical Analysis, 2012, 70, 523-528.	2.8	40
131	The folate metabolic network of Falciparum malaria. Molecular and Biochemical Parasitology, 2013, 188, 51-62.	1.1	40
132	Chloroquine resistance of Plasmodium falciparum: further evidence for a lack of association with mutations of the pfmdr1 gene. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 694.	1.8	39
133	The role of glutathione in the neurotoxicity of artemisinin derivatives in vitro22Abbreviations: AEM, artemether; DHA, dihydroartemisinin; and SOD, superoxide dismutase.. Biochemical Pharmacology, 2001, 61, 409-416.	4.4	39
134	Malaria parasite transporters as a drug-delivery strategy. Trends in Parasitology, 2005, 21, 299-301.	3.3	39
135	Towards a proteomic definition of CoArtem action inPlasmodium falciparum malaria. Proteomics, 2005, 5, 1849-1858.	2.2	39
136	Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of <i>Mycobacterium tuberculosis</i>. Journal of Medicinal Chemistry, 2017, 60, 3703-3726.	6.4	39
137	Distribution of acridine orange fluorescence in Plasmodium falciparum-infected erythrocytes and its implications for the evaluation of digestive vacuole pH. Molecular and Biochemical Parasitology, 2002, 119, 301-304.	1.1	38
138	Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?. ACS Infectious Diseases, 2021, 7, 1317-1331.	3.8	37
139	Malaria Chemotherapy. Advances in Parasitology, 2006, 61, 47-76.	3.2	36
140	Endoperoxide Carbonyl Falcipain 2/3 Inhibitor Hybrids: Toward Combination Chemotherapy of Malaria through a Single Chemical Entity. Journal of Medicinal Chemistry, 2010, 53, 8202-8206.	6.4	35
141	Reflections on the Nobel Prize for Medicine 2015 â€" The Public Health Legacy and Impact of Avermectin and Artemisinin. Trends in Parasitology, 2015, 31, 605-607.	3.3	35
142	Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis. Scientific Reports, 2016, 6, 23458.	3.3	35
143	Boron-Pleuromutilins as Anti-<i>Wolbachia</i> Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis. Journal of Medicinal Chemistry, 2019, 62, 2521-2540.	6.4	35
144	Determination of arteether in blood plasma by high-performance liquid chromatography with ultraviolet detection after hydrolysis with acid. Biomedical Applications, 1989, 493, 125-136.	1.7	34

#	Article	IF	Citations
145	Practical HPLC methods for the quantitative determination of common antimalarials in Africa. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 847, 231-236.	2.3	34
146	A rapid and sensitive HPLCâ€“MS method for the detection of plasma and cellular rifampicin. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 857, 76-82.	2.3	34
147	Chapter 17 Type II NADH: Quinone Oxidoreductases of Plasmodium Falciparum and Mycobacterium Tuberculosis. Methods in Enzymology, 2009, 456, 303-320.	1.0	34
148	The development of quinoloneesters as novel antimalarial agents targeting the Plasmodium falciparum bc1protein complex. MedChemComm, 2012, 3, 39-44.	3.4	34
149	Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi. Antimicrobial Agents and Chemotherapy, 2015, 59, 6175-6180.	3.2	34
150	Molecular surveillance for drug-resistant Plasmodiumfalciparum malaria in Malawi. Acta Tropica, 2007, 102, 138-142.	2.0	33
151	Role of Known Molecular Markers of Resistance in the Antimalarial Potency of Piperaquine and Dihydroartemisinin In Vitro. Antimicrobial Agents and Chemotherapy, 2009, 53, 1362-1366.	3.2	33
152	The pH of the Plasmodium falciparum digestive vacuole: holy grail or dead-end trail?. Trends in Parasitology, 2002, 18, 441-444.	3.3	32
153	An Endoperoxideâ€Based Hybrid Approach to Deliver Falcipain Inhibitors Inside Malaria Parasites. ChemMedChem, 2013, 8, 1528-1536.	3.2	32
154	The effect of variations in urinary pH on the pharmacokinetics of diethylcarbamazine.. British Journal of Clinical Pharmacology, 1981, 12, 807-812.	2.4	31
155	Rapid and sensitive method for the determination of albendazole and albendazole sulphoxide in biological fluids. Biomedical Applications, 1991, 566, 244-249.	1.7	31
156	Mechanism-Based Design of Parasite-Targeted Artemisinin Derivatives:Â Synthesis and Antimalarial Activity of Benzylamino and Alkylamino Ether Analogues of Artemisinin. Journal of Medicinal Chemistry, 1996, 39, 4511-4514.	6.4	31
157	Sulfadoxine-Pyrimethamineâ€“Based Combinations for Malaria: A Randomised Blinded Trial to Compare Efficacy, Safety and Selection of Resistance in Malawi. PLoS ONE, 2008, 3, e1578.	2.5	31
158	Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso. Journal of Antimicrobial Chemotherapy, 2014, 69, 2499-2507.	3.0	31
159	An efficient route into synthetically challenging bridged achiral 1,2,4,5-tetraoxanes with antimalarial activity. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1720-1724.	2.2	30
160	Lymphocyte subsets in healthy Malawians: Implications for immunologic assessment of HIV infection in Africa. Journal of Allergy and Clinical Immunology, 2010, 125, 203-208.	2.9	30
161	A simple breath test for tuberculosis using ion mobility: A pilot study. Tuberculosis, 2016, 99, 143-146.	1.9	30
162	Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration. Scientific Reports, 2017, 7, 502.	3.3	30

#	Article	IF	Citations
163	Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya. JMIR Research Protocols, 2016, 5, e213.	1.0	30
164	Rationale Design of Biotinylated Antimalarial Endoperoxide Carbon Centered Radical Prodrugs for Applications in Proteomics. Journal of Medicinal Chemistry, 2010, 53, 4555-4559.	6.4	29
165	Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity. PLoS Neglected Tropical Diseases, 2019, 13, e0007159.	3.0	29
166	Therapeutic potential of folate uptake inhibition in Plasmodium falciparum. Trends in Parasitology, 2004, 20, 109-112.	3.3	28
167	Chlorproguanilâ€“Dapsoneâ€“Artesunate versus Chlorproguanilâ€“Dapsone: A Randomized, Double-Blind, Phase III Trial in African Children, Adolescents, and Adults with Uncomplicated Plasmodium falciparum Malaria. American Journal of Tropical Medicine and Hygiene, 2009, 81, 969-978.	1.4	28
168	Second generation analogues of RKA182: synthetic tetraoxanes with outstanding in vitro and in vivo antimalarial activities. MedChemComm, 2011, 2, 661.	3.4	28
169	Sequence and gene expression of chloroquine resistance transporter (pfcrt) in the association of in vitro drugs resistance of Plasmodium falciparum. Malaria Journal, 2011, 10, 42.	2.3	28
170	Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	28
171	Potent Antimalarial 2-Pyrazolyl Quinolone <i>bc</i>₁ (Q_i) Inhibitors with Improved Drug-like Properties. ACS Medicinal Chemistry Letters, 2018, 9, 1205-1210.	2.8	28
172	Pharmacokineticsâ€Pharmacodynamics of Highâ€Dose Ivermectin with Dihydroartemisininâ€Piperaquine on Mosquitocidal Activity and <scp>QT</scp>â€Prolongation (<scp>IVERMAL</scp>). Clinical Pharmacology and Therapeutics, 2019, 105, 388-401.	4.7	28
173	The effects of primaquine stereoisomers and metabolites on drug metabolism in the isolated perfused rat liver and in vitro rat liver microsomes. Biochemical Pharmacology, 1985, 34, 331-336.	4.4	27
174	Potent Antihematozoan Activity of Novel Bisthiazolium Drug T16: Evidence for Inhibition of Phosphatidylcholine Metabolism in Erythrocytes Infected with Babesia and Plasmodium spp. Antimicrobial Agents and Chemotherapy, 2006, 50, 3381-3388.	3.2	27
175	Piperidine dispiro-1,2,4-trioxane analogues. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5804-5808.	2.2	27
176	Selective toxicity of dihydroartemisinin on human CD34+ erythroid cell differentiation. Toxicology, 2010, 276, 128-134.	4.2	27
177	Proteomic Analysis of Cerebrospinal Fluid in Pneumococcal Meningitis Reveals Potential Biomarkers Associated with Survival. Journal of Infectious Diseases, 2010, 202, 542-550.	4.0	27
178	In vivo kinetics of Wolbachia depletion by ABBV-4083 in L. sigmodontis adult worms and microfilariae. PLoS Neglected Tropical Diseases, 2019, 13, e0007636.	3.0	27
179	Anti-Wolbachia drugs for filariasis. Trends in Parasitology, 2021, 37, 1068-1081.	3.3	27
180	Malaria chemotherapy: Resistance to quinoline containing drugs inPlasmodium falciparum. FEMS Microbiology Letters, 1993, 113, 1-7.	1.8	26

#	ARTICLE	IF	CITATIONS
181	Optimisation of the allylsilane approach to C-10 deoxo carba analogues of dihydroartemisinin: synthesis and in vitro antimalarial activity of new, metabolically stable C-10 analogues. Journal of the Chemical Society, Perkin Transactions 1, 2001, , 2682-2689.	1.3	26
182	In Vitro Synergy and Enhanced Murine Brain Penetration of Saquinavir Coadministered with Mefloquine. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 1202-1209.	2.5	26
183	In vitro antimalarial drug susceptibility in Thai border areas from 1998-2003. Malaria Journal, 2005, 4, 37.	2.3	26
184	Synthesis and Antimalarial Activities of a Diverse Set of Triazoleâ€Containing Furamidine Analogues. ChemMedChem, 2011, 6, 2094-2108.	3.2	26
185	The biological evaluation of fusidic acid and its hydrogenation derivative as antimicrobial and anti-inflammatory agents. Infection and Drug Resistance, 2018, Volume 11, 1945-1957.	2.7	26
186	Diethylcarbamazine disposition in patients with onchocerciasis. Clinical Pharmacology and Therapeutics, 1981, 30, 551-557.	4.7	25
187	Potent Enhancement of the Sensitivity of Plasmodium falciparum to Chloroquine by the Bisbenzylisoquinoline Alkaloid Cepharanthin. Antimicrobial Agents and Chemotherapy, 2000, 44, 2706-2708.	3.2	25
188	Antimalarial Mannoxanes: Hybrid Antimalarial Drugs with Outstanding Oral Activity Profiles and A Potential Dual Mechanism of Action. ChemMedChem, 2011, 6, 1357-1361.	3.2	25
189	Cytochrome P-450 activity in malarial parasites and its possible relationship to chloroquine resistance. Molecular and Biochemical Parasitology, 1990, 41, 251-257.	1.1	24
190	The effect of malaria infection on paracetamol disposition in the rat. Biochemical Pharmacology, 1991, 41, 1707-1711.	4.4	24
191	Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. British Journal of Clinical Pharmacology, 2008, 66, 529-538.	2.4	24
192	Malaria-parasite mitochondrial dehydrogenases as drug targets: too early to write the obituary. Trends in Parasitology, 2008, 24, 9-10.	3.3	24
193	Identification and prioritization of novel anti- <i>Wolbachia</i> chemotypes from screening a 10,000-compound diversity library. Science Advances, 2017, 3, eaao1551.	10.3	24
194	Determination of halofantrine and its principal metabolite desbutylhalofantrine in biological fluids by reversed-phase high-performance liquid chromatography. Biomedical Applications, 1988, 433, 339-344.	1.7	23
195	Determination of midazolam and its major metabolite 1â€²-hydroxymidazolam by high-performance liquid chromatography-electrospray mass spectrometry in plasma from children. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 821, 1-7.	2.3	23
196	Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. British Journal of Clinical Pharmacology, 2006, 61, 289-300.	2.4	23
197	In Vivo and In Vitro Efficacy of Amodiaquine againstPlasmodium falciparumin an Area of Continued Use of 4â€Aminoquinolines in East Africa. Journal of Infectious Diseases, 2009, 199, 1575-1582.	4.0	23
198	Identification of Novel Antimalarial Chemotypes via Chemoinformatic Compound Selection Methods for a High-Throughput Screening Program against the Novel Malarial Target, PfNDH2: Increasing Hit Rate via Virtual Screening Methods. Journal of Medicinal Chemistry, 2012, 55, 3144-3154.	6.4	23

#	Article	IF	Citations
199	Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients. Antimicrobial Agents and Chemotherapy, 2014, 58, 7164-7170.	3.2	23
200	Lymphocyte Perturbations in Malawian Children with Severe and Uncomplicated Malaria. Vaccine Journal, 2016, 23, 95-103.	3.1	23
201	Biguanide-Atovaquone Synergy against Plasmodium falciparum In Vitro. Antimicrobial Agents and Chemotherapy, 2002, 46, 2700-2703.	3.2	22
202	Parasites bearing a single copy of the multi-drug resistance gene (pfmdr-1) with wild-type SNPs predominate amongst Plasmodium falciparum isolates from Malawi. Acta Tropica, 2009, 111, 78-81.	2.0	22
203	Population Pharmacokinetics of Sulfadoxine and Pyrimethamine in Malawian Children With Malaria. Clinical Pharmacology and Therapeutics, 2011, 89, 268-275.	4.7	22
204	Plasma and Cerebrospinal Proteomes From Children With Cerebral Malaria Differ From Those of Children With Other Encephalopathies. Journal of Infectious Diseases, 2013, 208, 1494-1503.	4.0	22
205	The potential of desipramine to reverse chloroquine resistance of Plasmodium falciparum is reduced by its binding to plasma protein. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87, 303.	1.8	21
206	Clinical Pharmacokinetics in the Treatment of Tropical Diseases. Clinical Pharmacokinetics, 1994, 27, 150-165.	3.5	21
207	Effect of malaria infection and endotoxin-induced fever on phenacetin o-deethylation by rat liver microsomes. Biochemical Pharmacology, 1993, 45, 1235-1241.	4.4	20
208	Open-Label Comparative Clinical Study of Chlorproguanilâ˘'Dapsone Fixed Dose Combination (Lapdapâ„¢) Alone or with Three Different Doses of Artesunate for Uncomplicated Plasmodium falciparum Malaria. PLoS ONE, 2008, 3, e1779.	2.5	20
209	A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children. British Journal of Clinical Pharmacology, 2016, 81, 679-687.	2.4	20
210	Application of the TMSOTfî—¸AgClO4 activator system to the synthesis of novel, potent, C-10 phenoxy derivatives of dihydroartemisinin. Tetrahedron Letters, 1999, 40, 9129-9132.	1.4	19
211	Dielsâ€"Alder/thiolâ€"olefin co-oxygenation approach to antimalarials incorporating the 2,3-dioxabicyclo[3.3.1]nonane pharmacophore. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2991-2995.	2.2	19
212	Synthesis and biological activities of 4-N-(anilinyl-n-[oxazolyl])-7-chloroquinolines (n=3â€² or 4â€²) against Plasmodium falciparum in in vitro models. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4512-4515.	2.2	19
213	Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers. Bioorganic and Medicinal Chemistry, 2013, 21, 7392-7397.	3.0	19
214	A Click Chemistryâ€Based Proteomic Approach Reveals that 1,2,4â€Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile. Angewandte Chemie, 2016, 128, 6511-6515.	2.0	19
215	Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	18
216	Intra-host dynamics of co-infecting parasite genotypes in asymptomatic malaria patients. Infection, Genetics and Evolution, 2018, 65, 414-424.	2.3	18

#	Article	IF	Citations
217	The disposition of primaquine in the isolated perfused rat liver. Biochemical Pharmacology, 1987, 36, 3365-3369.	4.4	17
218	Quantitative determination of carbaryl and carbaryl metabolites by reversed-phase high-performance liquid chromatography. Journal of Chromatography A, 1987, 388, 462-466.	3.7	17
219	Metabolism of gestodene in human liver cytosol and microsomes in vitro. Journal of Steroid Biochemistry and Molecular Biology, 1993, 46, 235-243.	2.5	17
220	Carbamoyl Triazoles, Known Serine Protease Inhibitors, Are a Potent New Class of Antimalarials. Journal of Medicinal Chemistry, 2015, 58, 6448-6455.	6.4	17
221	Further comments on the distribution of acridine orange fluorescence in P. falciparumâ€“infected erythrocytes. Molecular and Biochemical Parasitology, 2002, 119, 311-313.	1.1	16
222	Comparative preclinical drug metabolism and pharmacokinetic evaluation of novel 4-aminoquinoline anti-malarials. Journal of Pharmaceutical Sciences, 2009, 98, 362-377.	3.3	16
223	Synthesis, in vitro and in vivo antimalarial assessment of sulfide, sulfone and vinyl amide-substituted 1,2,4-trioxanes prepared via thiol-olefin co-oxygenation (TOCO) of allylic alcohols. Organic and Biomolecular Chemistry, 2010, 8, 2068.	2.8	16
224	Short-course, oral flubendazole does not mediate significant efficacy against Onchocerca adult male worms or Brugia microfilariae in murine infection models. PLoS Neglected Tropical Diseases, 2019, 13, e0006356.	3.0	16
225	Mechanisms of chloroquine resistance in malarial chemotherapy. Trends in Pharmacological Sciences, 1988, 9, 241-246.	8.7	15
226	CRIMALDDI: platform technologies and novel anti-malarial drug targets. Malaria Journal, 2013, 12, 396.	2.3	15
227	Human Direct Skin Feeding Versus Membrane Feeding to Assess the Mosquitocidal Efficacy of High-Dose Ivermectin (IVERMAL Trial). Clinical Infectious Diseases, 2019, 69, 1112-1119.	5.8	15
228	Effect of malaria infection and endotoxin-induced fever on the metabolism of antipyrine and metronidazole in the rat. Biochemical Pharmacology, 1993, 45, 1243-1249.	4.4	14
229	Death Is Associated with Complement C3 Depletion in Cerebrospinal Fluid of Patients with Pneumococcal Meningitis. MBio, 2012, 3, .	4.1	14
230	Metabolite footprinting of Plasmodium falciparum following exposure to Garcinia mangostana Linn. crude extract. Experimental Parasitology, 2014, 145, 80-86.	1.2	14
231	2-Pyridylquinolone antimalarials with improved antimalarial activity and physicochemical properties. MedChemComm, 2015, 6, 1252-1259.	3.4	14
232	Optimisation of the synthesis of second generation 1,2,4,5 tetraoxane antimalarials. Tetrahedron, 2016, 72, 6118-6126.	1.9	14
233	Novel anti-Wolbachia drugs, a new approach in the treatment and prevention of veterinary filariasis?. Veterinary Parasitology, 2020, 279, 109057.	1.8	14
234	The effect of malaria infection on antipyrine metabolite formation in the rat. Biochemical Pharmacology, 1991, 41, 1264-1266.	4.4	13

#	Article	IF	Citations
235	Na+/H+ Antiporter, Chloroquine Uptake and Drug Resistance: Inconsistencies in a Newly Proposed Model. Parasitology Today, 1999, 15, 360-363.	3.0	13
236	Is reversal of chloroquine resistance ready for the clinic?. Lancet, The, 2001, 357, 904.	13.7	13
237	Mutations Conferring Drug Resistance in Malaria Parasite Drug Transporters Pgh1 and PfCRT Do Not Affect Steady-State Vacuolar Ca 2+. Antimicrobial Agents and Chemotherapy, 2005, 49, 4807-4808.	3.2	13
238	Synthesis of 1,2,4-trioxepanes via application of thiol-olefin Co-oxygenation methodology. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 6124-6130.	2.2	13
239	Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. European Journal of Clinical Pharmacology, 2009, 65, 977-987.	1.9	13
240	Suboptimal Exposure to Antiâ€TB Drugs in a TBM/HIV+ Population Is Not Related to Antiretroviral Therapy. Clinical Pharmacology and Therapeutics, 2018, 103, 449-457.	4.7	13
241	Determination of suramin in plasma by high-performance liquid chromatography. Biomedical Applications, 1985, 343, 224-228.	1.7	12
242	The disposition of pyrimethamine in the isolated perfused rat liver. Biochemical Pharmacology, 1985, 34, 2193-2197.	4.4	12
243	Examination of the Cytotoxic and Embryotoxic Potential and Underlying Mechanisms of Next-Generation Synthetic Trioxolane and Tetraoxane Antimalarials. Molecular Medicine, 2012, 18, 1045-1055.	4.4	12
244	A Quinoline Carboxamide Antimalarial Drug Candidate Uniquely Targets Plasmodia at Three Stages of the Parasite Life Cycle. Angewandte Chemie - International Edition, 2015, 54, 13504-13506.	13.8	12
245	Synthesis and structureâ€“activity relationship of N⁴-benzylamine-N²-isopropyl-quinazoline-2,4-diamines derivatives as potential antibacterial agents. RSC Advances, 2017, 7, 52227-52237.	3.6	12
246	Decomposition reactions of arteether, a semisynthetic derivative of qinghaosu (artemisinin). Tetrahedron, 1990, 46, 1871-1884.	1.9	11
247	Lewis acid catalysed rearrangements of unsaturated bicyclic [2.2.n] endoperoxides in the presence of vinyl silanes; access to novel Fenozan BO-7 analogues. Tetrahedron Letters, 2005, 46, 3029-3032.	1.4	11
248	<i>Plasmodium falciparum</i> Strains Harboring Dihydrofolate Reductase with the I164L Mutation Are Absent in Malawi and Zambia Even under Antifolate Drug Pressure. Antimicrobial Agents and Chemotherapy, 2008, 52, 3883-3888.	3.2	11
249	Oral Activated Charcoal Prevents Experimental Cerebral Malaria in Mice and in a Randomized Controlled Clinical Trial in Man Did Not Interfere with the Pharmacokinetics of Parenteral Artesunate. PLoS ONE, 2010, 5, e9867.	2.5	11
250	Global proteomic analysis of plasma from mice infected with Plasmodium berghei ANKA using two dimensional gel electrophoresis and matrix assisted laser desorption ionization-time of flight mass spectrometry. Malaria Journal, 2011, 10, 205.	2.3	11
251	Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria. Bioorganic and Medicinal Chemistry, 2018, 26, 2996-3005.	3.0	11
252	Development of a High-Throughput Cytometric Screen to Identify Anti-Wolbachia Compounds: The Power of Publicâ€“Private Partnership. SLAS Discovery, 2019, 24, 537-547.	2.7	11

#	Article	IF	Citations
253	Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis. Open Forum Infectious Diseases, 2020, 7, ofaa218.	0.9	11
254	The effect of fluorine substitution on the antimalarial activity of tebuquine. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 391-392.	2.2	10
255	4-Aminoquinolines: Chloroquine, Amodiaquine and Next-Generation Analogues. , 2011, , 19-44.		10
256	In vivo efficacy of the boron-pleuromutilin AN11251 against Wolbachia of the rodent filarial nematode Litomosoides sigmodontis. PLoS Neglected Tropical Diseases, 2020, 14, e0007957.	3.0	10
257	The effect of fluorine substitution on the haemotoxicity of Primaquine. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 2309-2314.	2.2	9
258	Study on the biochemical basis of mefloquine resistant Plasmodium falciparum. Experimental Parasitology, 2007, 117, 141-148.	1.2	9
259	M1 macrophage features in severe Plasmodium falciparum malaria patients with pulmonary oedema. Malaria Journal, 2020, 19, 182.	2.3	9
260	Chloroquine Uptake and Activity is Determined by Binding to Ferriprotoporphyrin IX in <i>Plasmodium Falciparum</i>. Novartis Foundation Symposium, 1999, 226, 252-264.	1.1	9
261	Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data. BMC Medicine, 2022, 20, 85.	5.5	9
262	The pharmacokinetics of (+)- and (â^')-primaquine in the isolated perfused rat liver preparation. Biochemical Pharmacology, 1987, 36, 2238-2239.	4.4	8
263	Molecular cloning of a gene encoding a 20S proteasome Î² subunit from Plasmodium falciparum. International Journal for Parasitology, 2000, 30, 729-733.	3.1	7
264	Drug-Regulated Expression of<i>Plasmodium falciparum</i>P-Glycoprotein Homologue 1: a Putative Role for Nuclear Receptors. Antimicrobial Agents and Chemotherapy, 2008, 52, 1438-1445.	3.2	7
265	A yeast expression system for functional and pharmacological studies of the malaria parasite Ca2+/H+ antiporter. Malaria Journal, 2012, 11, 254.	2.3	7
266	Artemisininâ€"Polypyrrole Conjugates: Synthesis, DNA Binding Studies and Preliminary Antiproliferative Evaluation. ChemMedChem, 2013, 8, 709-718.	3.2	7
267	The Nobel Prize in Medicine 2015: Two drugs that changed global health. Science Translational Medicine, 2015, 7, 316ed14.	12.4	7
268	Exploring pancreatic pathology in Plasmodium falciparum malaria patients. Scientific Reports, 2018, 8, 10456.	3.3	7
269	Pharmacokinetics of TKM-130803Âin Sierra Leonean patients withÂEbola virus disease: Âplasma concentrations exceed target levels, withÂdrugÂaccumulation in the most severe patients. EBioMedicine, 2020, 52, 102601.	6.1	7
270	Remdesivirâ€"ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2. International Journal of Antimicrobial Agents, 2022, 59, 106542.	2.5	7

#	Article	IF	Citations
271	<i>Wolbachia</i> depletion blocks transmission of lymphatic filariasis by preventing chitinase-dependent parasite exsheathment. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2120003119.	7.1	7
272	CRIMALDDI: a co-ordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives. Malaria Journal, 2010, 9, 202.	2.3	6
273	Antimalarial activity of isoquine against Kenyan Plasmodium falciparum clinical isolates and association with polymorphisms in pfcrt and pfmdr1 genes. Journal of Antimicrobial Chemotherapy, 2013, 68, 786-788.	3.0	6
274	Chloroquine sensitivity of Plasmodium falciparum in vivo in a savanna town in Cameroon. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1992, 86, 229-230.	1.8	5
275	Drug resistance in parasites. , 2003, , 397-432.		5
276	Influence of the pfmdr1 Gene on In Vitro Sensitivities of Piperaquine in Thai Isolates of Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene, 2017, 96, 16-0668.	1.4	5
277	Enantioselective Synthesis and Profiling of Potent, Nonlinear Analogues of Antimalarial Tetraoxanes E209 and N205. ACS Medicinal Chemistry Letters, 2021, 12, 1077-1085.	2.8	5
278	Development of Pyrazolopyrimidine Anti-<i>Wolbachia</i> Agents for the Treatment of Filariasis. ACS Medicinal Chemistry Letters, 2021, 12, 1421-1426.	2.8	5
279	Determination of artelinic acid in blood plasma by high-performance liquid chromatography. Biomedical Applications, 1989, 495, 167-177.	1.7	4
280	Lack of effect of halofantrine on hepatic drug metabolism in the rat in vivo and in vitro. Biochemical Pharmacology, 1990, 39, 1581-1586.	4.4	4
281	Altered binding of chloroquine to ferriprotoporphyrin IX is the basis for chloroquine resistance. Drug Resistance Updates, 1999, 2, 97-103.	14.4	4
282	Definitive proof for a role of pfmdr 1 in quinoline resistance in Plasmodium falciparum. Drug Resistance Updates, 2000, 3, 80-81.	14.4	4
283	Pharmacokinetic modelling of the anti-malarial drug artesunate and its active metabolite dihydroartemisinin. Computer Methods and Programs in Biomedicine, 2013, 112, 1-15.	4.7	4
284	Intra-individual effects of food upon the pharmacokinetics of rifampicin and isoniazid. Journal of Antimicrobial Chemotherapy, 2019, 74, 416-424.	3.0	4
285	Intracellular PD Modelling (PDi) for the Prediction of Clinical Activity of Increased Rifampicin Dosing. Pharmaceutics, 2019, 11, 278.	4.5	4
286	The effect of 2,2â€²-substitution on the metabolism and toxicity of dapsone in vitro and in vivo. Environmental Toxicology and Pharmacology, 1998, 5, 145-153.	4.0	3
287	Intracellular Pharmacodynamic Modeling Is Predictive of the Clinical Activity of Fluoroquinolones against Tuberculosis. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	3
288	Carbaryl Metabolism is Inhibited by Ctmetidine in the Isolated Perfused Rat Liver and in Man. Journal of Toxicology: Clinical Toxicology, 1988, 26, 269-281.	1.5	2

#	Article	IF	Citations
289	Inter-individual variation in the metabolic activation of the antimalarial biguanides. Parasitology Today, 1991, 7, 120-123.	3.0	2
290	Could Proteomic Research Deliver the Next Generation of Treatments for Pneumococcal Meningitis?. Interdisciplinary Perspectives on Infectious Diseases, 2009, 2009, 1-11.	1.4	2
291	A novel drug for uncomplicated malaria: targeted high throughput screening (HTS) against the type II NADH:ubiquinone oxidoreductase (PfNdh2) of Plasmodium falciparum. Malaria Journal, 2010, 9, .	2.3	2
292	CRIMALDDI: a prioritized research agenda to expedite the discovery of new anti-malarial drugs. Malaria Journal, 2013, 12, 395.	2.3	2
293	Proteomics analysis of antimalarial targets of Garcinia mangostana Linn.. Asian Pacific Journal of Tropical Biomedicine, 2014, 4, 515-519.	1.2	2
294	Mechanisms of Antimalarial Drug Resistance. , 2017, , 629-647.		2
295	<i>Plasmodium falciparum</i> and Dihydrofolate Reductase I164L Mutations in Africa. Antimicrobial Agents and Chemotherapy, 2009, 53, 1722-1723.	3.2	1
296	Mechanisms of Antimalarial Drug Resistance. , 2009, , 561-574.		1
297	Reprint of â€œPharmacokinetic modelling of the anti-malarial drug artesunate and its active metabolite dihydroartemisininâ€• Computer Methods and Programs in Biomedicine, 2014, 114, e14-e28.	4.7	1
298	OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens. Malaria Journal, 2016, 15, 344.	2.3	1
299	Inhibitors of the Plasmodium Mitochondrial Respiratory Chain. , 2014, , 1-18.		1
300	Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Burkina Faso: an open label trial. Wellcome Open Research, 2019, 4, 45.	1.8	1
301	Dangerous midwives and hemoglobin degradation: a response. Trends in Parasitology, 2003, 19, 199-200.	3.3	0
302	Co(thd)2: A Superior Catalyst for Aerobic Epoxidation and Hydroperoxysilylation of Unactivated Alkenes: Application to the Synthesis of Spiro-1,2,4-trioxanes.. ChemInform, 2004, 35, no.	0.0	0
303	A novel drug for uncomplicated malaria: Targeted high throughput screening (HTS) against the type II NADH:ubiquinone oxidoreductase (PfNDH2) of Plasmodium falciparum. Biochimica Et Biophysica Acta - Bioenergetics, 2010, 1797, 80.	1.0	0
304	Pharmacokinetic modelling of the anti-malarial drug artesunate and its active metabolite dihydroartemisinin. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2012, 45, 266-271.	0.4	0
305	A novel fluorescent probe for the detection of AmpC beta-lactamase and the application in screening beta-lactamase inhibitors. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2020, 234, 118257.	3.9	0
306	Mitochondrial Electron Transport Chain of Plasmodium falciparum. , 2014, , 1-14.		0

#	Article	IF	Citations
307	Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Burkina Faso: an open label trial. Wellcome Open Research, 0, 4, 45.	1.8	0
308	Pharmacokinetics of TKM-130803 in Ebola virus disease in Sierra Leonean subjects. Access Microbiology, 2020, 2, .	0.5	0